1-4 of 4
atypical hemolytic-uremic syndrome
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome

Clinical Trials & Observations
Shruti Chaturvedi, Noor Dhaliwal, Sarah Hussain, Kathryn Dane, Harshvardhan Upreti, Evan M. Braunstein, Xuan Yuan, C. John Sperati, Alison R. Moliterno, Robert A. Brodsky
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1504–1512.
https://doi.org/10.1182/bloodadvances.2020003175
Published: 2021
Journal Articles

Potentiation of complement regulator factor H protects human endothelial cells from complement attack in aHUS sera

Richard B. Pouw, Mieke C. Brouwer, Marlon de Gast, Anna E. van Beek, Lambertus P. van den Heuvel, Christoph Q. Schmidt, Arie van der Ende, Pilar Sánchez-Corral, Taco W. Kuijpers, Diana Wouters
Journal: Blood Advances
Blood Adv (2019) 3 (4): 621–632.
https://doi.org/10.1182/bloodadvances.2018025692
Published: 2019
Includes: Supplemental data
Journal Articles

Carfilzomib-induced aHUS responds to early eculizumab and may be associated with heterozygous CFHR3-CFHR1 deletion

Clinical Trials & Observations
Andrew Jay Portuguese, Brea Lipe
Journal: Blood Advances
Blood Adv (2018) 2 (23): 3443–3446.
https://doi.org/10.1182/bloodadvances.2018027532
Published: 2018
Journal Articles

Complement-mediated thrombotic microangiopathy associated with lupus nephritis

Mi Hee Park, Nicholas Caselman, Scott Ulmer, Ilene Ceil Weitz
Journal: Blood Advances
Blood Adv (2018) 2 (16): 2090–2094.
https://doi.org/10.1182/bloodadvances.2018019596
Published: 2018